DDLS
MCID: DDF001
MIFTS: 43

Dedifferentiated Liposarcoma (DDLS) malady

Category: Rare diseases

Aliases & Classifications for Dedifferentiated Liposarcoma

About this section
Sources:
31ICD10 via Orphanet, 50Novoseek, 54Orphanet, 68UMLS, 69UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Dedifferentiated Liposarcoma:

Name: Dedifferentiated Liposarcoma 54
Liposarcoma, Dedifferentiated 68
 
Liposarcoma Dedifferentiated 50
Ddls 54

Characteristics:

Orphanet epidemiological data:

54
dedifferentiated liposarcoma:
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Adult; Age of death: adult

Classifications:



External Ids:

Orphanet54 ORPHA99970
UMLS via Orphanet69 C0205824
ICD10 via Orphanet31 C49.9

Summaries for Dedifferentiated Liposarcoma

About this section
MalaCards based summary: Dedifferentiated Liposarcoma, also known as liposarcoma, dedifferentiated, is related to liposarcoma and primary eye hypotony. An important gene associated with Dedifferentiated Liposarcoma is MDM2 (MDM2 Proto-Oncogene), and among its related pathways are Aurora A signaling and GADD45 Pathway. Affiliated tissues include bone, lung and colon, and related mouse phenotypes are digestive/alimentary and pigmentation.

Related Diseases for Dedifferentiated Liposarcoma

About this section

Diseases related to Dedifferentiated Liposarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 180)
idRelated DiseaseScoreTop Affiliating Genes
1liposarcoma10.9
2primary eye hypotony10.3CDK4, MDM2
3amelogenesis imperfecta-gingival hyperplasia syndrome10.3CDK4, MDM2
4blood protein disease10.3CDK4, MDM2
5liposarcoma of bone10.3CDK4, MDM2
6bone leiomyosarcoma10.3CDK4, MDM2
7localized hypertrophic neuropathy10.3CDK4, MDM2
8malignant mixed mullerian tumor10.2DES, HMGA2
9intracranial liposarcoma10.2CDK4, MDM2
10breast rhabdomyosarcoma10.2DES, HMGA2
11transitional cell carcinoma10.2DES, HMGA2
12heart sarcoma10.2CDKN2A, HMGA2
13carbon monoxide-induced parkinsonism10.2ACTC1, DES
14endometrial disease10.2CDK4, CDKN2A
15vagina leiomyosarcoma10.2ACTC1, DES
16myoma10.2ACTC1, DES
17spleen angiosarcoma10.2ACTC1, DES
18malignant dermis tumor10.2ACTC1, DES
19reticulohistiocytic granuloma10.2DES, F13A1
20acute mountain sickness10.2MDM2, TP53
21polydactyly cleft lip palate psychomotor retardation10.2CDKN2A, DES
22biemond syndrome10.2ACTC1, DES
23intestinal obstruction10.2ACTC1, DES
24functionless pituitary adenoma10.2MDM2, TP53
25scarlet fever10.2MDM2, TP53
26cavernous sinus meningioma10.2DES, F13A1
27extraosseous osteosarcoma10.2CDK4, DES, MDM2
28male urethral cancer10.2ACTC1, DES
29verruciform xanthoma of skin10.2DES, TP53
30pinta disease10.2CDK4, MDM2
31sarcoma10.2
32rhabdomyosarcoma 2, alveolar10.2CDK4, DES, MDM2
33pustulosis palmaris et plantaris10.2ACTC1, DES
34dystrophic epidermolysis bullosa, nails only10.2ACTC1, F13A1
35secondary adrenal insufficiency10.1ACTC1, F13A1
36pleural lipoma10.1CDK4, HMGA2, MDM2
37childhood immature teratoma of ovary10.1CDK4, HMGA2, MDM2
38embryonal extrahepatic bile duct rhabdomyosarcoma10.1CDK4, DES, MDM2
39clear cell adenofibroma10.1CDKN2A, TP53
40lacrimal gland adenoid cystic carcinoma10.1CDKN2A, TP53
41aortic aneurysm10.1CDK4, CDKN2A, MDM2
42apocrine sweat gland neoplasm10.1CDK4, CDKN2A, MDM2
43serous surface papilloma10.1ACTC1, HMGA2
44hormone producing pituitary cancer10.1CDK4, MDM2
45sebaceous adenoma10.1ACTC1, DES
46multifocal osteogenic sarcoma10.1CDK4, CDKN2A, MDM2
47spondylarthropathy10.1CDKN2A, TP53
48histiocytoma10.1
49fibrous histiocytoma10.1
50bone deterioration disease10.1DES, TP53

Graphical network of the top 20 diseases related to Dedifferentiated Liposarcoma:



Diseases related to dedifferentiated liposarcoma

Symptoms & Phenotypes for Dedifferentiated Liposarcoma

About this section

MGI Mouse Phenotypes related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053818.8CDK4, CDKN2A, MDM2, MET, TP53
2MP:00011868.7CDK4, CDKN2A, MDM2, TP53
3MP:00053708.7CDK4, CDKN2A, MDM2, MET, TP53
4MP:00020068.6CDK4, CDKN2A, MDM2, MET, TP53
5MP:00053798.2CDK4, CDKN2A, F13A1, MDM2, MET, TP53
6MP:00053847.8ACTC1, CDK4, CDKN2A, DES, MDM2, MET
7MP:00053697.7ACTC1, CDK4, CDKN2A, DES, MDM2, MET
8MP:00053857.3ACTC1, CDK4, CDKN2A, DES, F13A1, MDM2
9MP:00053767.3ACTC1, CDK4, CDKN2A, DES, F13A1, MDM2
10MP:00107687.2ACTC1, CDK4, CDKN2A, DES, F13A1, MDM2

Drugs & Therapeutics for Dedifferentiated Liposarcoma

About this section

Drugs for Dedifferentiated Liposarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 23)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Rosiglitazoneapproved, investigationalPhase 2220122320-73-477999
Synonyms:
(RS)-5-{4-[2-(Methyl-2-pyridylamino)ethoxy]benzyl}-2,4-thiazolidinedion
(±)-5-[p-[2-(methyl-2-pyridylamino)ethoxy]benzyl]-2,4-thiazolidinedione
122320-73-4
2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI)
5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione
5-((4-(2-Methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate
5-(4-{2-[methyl(pyridin-2-yl)amino]ethoxy}benzyl)-1,3-thiazolidine-2,4-dione
5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
5-[[4-[2-(methyl-(2-pyridyl)amino)ethoxy]phenyl]methyl] thiazolidine-2,4-dione
5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
AC-3459
AC1L2U9N
Avandia
BRD-A97437073-001-02-3
BRD-A97437073-001-03-1
BRL49653
BSPBio_002693
Brl 49653
Brl-49653
C18H19N3O3S
CID77999
D08491
DB00412
Gaudil
Gaudil (TN)
HMS1922J11
HMS2094O13
HSDB 7555
I06-0141
IDMB (1uM BRL49653, 1uM Dexamethasone, 0.5uM IBMX, 10ug/mL Insulin)
KBio2_002183
KBio2_004751
KBio2_007319
KBio3_001913
 
KBioGR_001609
KBioSS_002183
LS-151340
MolPort-002-508-212
NCGC00095124-01
NCGC00095124-02
NCGC00095124-03
RGZ
RSG
Rosi
Rosigilitazone
Rosigliazone maleate
Rosiglitazon
Rosiglitazona
Rosiglitazone
Rosiglitazone (INN)
Rosiglitazone [INN:BAN]
Rosiglitazone maleate
Rosiglitazonum
Rosiglizole
S00306
SPBio_001142
SPECTRUM1504263
STOCK6S-23924
Spectrum2_001241
Spectrum3_000997
Spectrum4_001125
Spectrum5_001464
Spectrum_001703
TDZ 01
UNII-05V02F2KDG
[3H]rosiglitazone
rosiglitazona
rosiglitazone
rosiglitazone (Avandia)
rosiglitazonum
2
Trabectedinapproved, investigationalPhase 273114899-77-3108150
Synonyms:
ET-743
ET743
 
Ecteinascidin
Ecteinascidin 743
NSC 684766
3
EverolimusapprovedPhase 21940159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
everolimus
4
PembrolizumabapprovedPhase 25071374853-91-4
Synonyms:
Keytruda
 
MK-3475
lambrolizumab
5
MesnaapprovedPhase 22633375-50-6598
Synonyms:
2-Mercaptoethane
2-Mercaptoethanesulfonate
2-Mercaptoethanesulfonic acid
2-mercaptoethanesulfonic acid
2-mercaptoethanesulphonic acid
2-mercaptoethylsulfonate
2-sulfanylethylsulfonate
 
CoM
Coenzima M
Coenzym M
Coenzyme M
HS-CoM
reduced CoM
reduced coenzyme M
β-mercaptoethanesulfonic acid
6
Cyclophosphamideapproved, investigationalPhase 2293550-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
7
MechlorethamineapprovedPhase 239751-75-24033
Synonyms:
.Beta.,.beta.'-Dichlorodiethyl-N-methylamine
1, 5-Dichloro-3-methyl-3-azapentane hydrochloride
126-85-2 (N-oxide)
2,2'-Dichloro-N-me
2,2'-Dichloro-N-methyldiethylamine
2,2'-Dichlorodiethyl-methylamine
2,2'-dichloro-N-methyldiethylamine
2-Chloro-N-(2-chloroethyl)-N-methylethanamine
302-70-5 (N-oxide, hydrochloride)
51-75-2
55-86-7 (HYDROCHLORIDE)
AC1L1H9H
Antimit
BRN 0605323
BSPBio_001947
Bis(2-chloroethyl)methylamine
Bis(beta-chloroethyl) methylamine
Bis(beta-chloroethyl)methylamine
C07115
C5H11Cl2N
CCRIS 447
CHEBI:28925
CHEMBL427
CID4033
Carolysine
Caryolysin
Caryolysine
Chloramine (the nitrogen mustard)
Chlorethazine
Chlormethine
Chlormethine (INN)
Chlormethine [INN:BAN]
Chlormethinum [INN-Latin]
Cloramin
Clormetina
Clormetina [INN-Spanish]
D07671
DB00888
Di(2-chloroethyl)methylamine
Dichlor amine
Dichloren
DivK1c_000759
EINECS 200-120-5
ENT-25294
Embechine
Embichin
HMS1920J15
HMS2091B04
HMS502F21
HN-2
HN2
HSDB 5083
I14-8708
IBS-L0033631
IDI1_000759
KBio1_000759
KBio2_001369
KBio2_003937
KBio2_006505
KBio3_001447
 
KBioGR_001448
KBioSS_001369
LS-7559
MBA
Me chloroethamine
Mebichloramine
Mechlorethamine
Mechlorethanamine
Mechloroethamine
Mecloretamina
Mecloretamina [Italian]
Methylbis(2-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Methyldi(2-chloroethyl)amine
Mitoxine (*Hydrochloride*)
MolPort-001-785-592
Mustargen
Mustine
Mustine note
Mutagen
N,N-Bis(2-chloroethyl)-N-methylamine
N,N-Bis(2-chloroethyl)methylamine
N,N-Di(chloroethyl)methylamine
N-Lost
N-Methyl lost
N-Methyl-2,2'-dichlorodiethylamine
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-Methyl-bis-chloraethylamin
N-Methyl-bis-chloraethylamin [German]
N-Methyl-lost
N-Methyl-lost [German]
N-methyl-bis(2-chloroethyl)amine
NCGC00091835-02
NCGC00091835-03
NCGC00091835-04
NCGC00091835-05
NCI60_041682
NINDS_000759
NSC762
Nitol (*Hydrochloride*)
Nitrogen mustard
Nitrogen mustard (HN-2)
Nitrogranulogen
SPBio_000496
SPECTRUM1500375
Spectrum2_000448
Spectrum3_000484
Spectrum4_000924
Spectrum5_001702
Spectrum_000889
Stickstofflost (*Hydrochloride*)
Stickstofflost (ebewe)
T 1024
T-1024
TL 146
UNII-50D9XSG0VR
beta,Beta'-dichlorodiethyl-N-methylamine
beta,beta'-Dichlorodiethyl-N-methylamine
mechlorethamine
thyldiethylamine
β,β'-dichlorodiethyl-N-methylamine
8
Sirolimusapproved, investigationalPhase 2194053123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
9
IfosfamideapprovedPhase 24003778-73-23690
Synonyms:
(+-)-Ifosfamid
(+-)-Ifosphamide
(+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
(D,L)-Ifosfamide
(R,S)-Ifosphamide
(R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd
2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI)
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
3,} 2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
36341-88-5
3778-73-2
84711-20-6
A 4942
AB00513932
AC-2113
AC1L1GHW
ASTA Z 4942
Ambap3778-73-2
Asta Z 4942
BPBio1_000865
BRN 0611835
BSPBio_000785
C07047
CAS-3778-73-2
CCRIS 352
CHEBI:5864
CHEMBL1024
CID3690
Cyfos
D00343
D007069
DB01181
EINECS 223-237-3
HMS1570H07
HMS2090M12
HMS2093N07
HSDB 7023
Holoxan
Holoxan 1000
I-Phosphamide
I06-0494
IFEX (TN)
Ifex
Ifosfamid
Ifosfamida
Ifosfamida [INN-Spanish]
Ifosfamide (JAN/USP/INN)
 
Ifosfamide Sterile
Ifosfamide [USAN:INN:BAN:JAN]
Ifosfamidum
Ifosfamidum [INN-Latin]
Ifosphamide
Ifsofamide
Iphosphamid
Iphosphamid(e)
Iphosphamide
Iso Endoxan
Iso-Endoxan
Isoendoxan
Isofosfamide
Isophosphamide
Isosfamide
LS-102
LS-99799
MJF 9325
MJF-9325
MLS002154021
Mitoxana
Mitoxana, Ifex, Ifosfamide
MolPort-003-666-704
N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide
N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine
NCGC00016639-01
NCGC00179435-01
NCI-C01638
NCI60_000233
NPFAPI-04
NSC 109,724
NSC 109724
NSC-109,724
NSC-109724
NSC109,724
NSC109724
Naxamide
Prestwick0_000833
Prestwick1_000833
Prestwick2_000833
Prestwick3_000833
S1302_Selleck
SMR001233348
SPBio_002706
STL058690
UNII-UM20QQM95Y
WLN: T6NPOTJ AM2G BO B2G
Z 4942
Z-4942
Z4942
ifosfamide
isosfamide
{3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,
10
Miconazoleapproved, investigational, vet_approvedPhase 2370622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
11
Maleic acidexperimentalPhase 2296110-16-7444266
Synonyms:
(2Z)-2-Butenedioate
(2Z)-2-Butenedioic acid
(2Z)-Butene-2-dioate
(2Z)-Butene-2-dioic acid
(2Z)-but-2-enedioate
(2Z)-but-2-enedioic acid
(Z)-2-Butenedioate
(Z)-2-Butenedioic acid
(z)-butenedioate
(z)-butenedioic acid
2-Butenedioate
2-Butenedioic acid
Cis-butenedioate
Cis-butenedioic acid
 
H2male
Kyselina maleinova
MAE
Maleate
Maleic acid
Maleic acid [NA2215]
Maleinic acid
Malenic acid
Malezid CM
Scotchbond multipurpose etchant
Toxilic acid
cis-1,2-Ethylenedicarboxylic acid
cis-2-Butenedioate
cis-2-Butenedioic acid
cis-But-2-enedioate
cis-But-2-enedioic acid
12Hypoglycemic AgentsPhase 25896
13Antirheumatic AgentsPhase 210956
14Immunosuppressive AgentsPhase 213086
15Anti-Infective AgentsPhase 222062
16ImmunoglobulinsPhase 26394
17Antineoplastic Agents, AlkylatingPhase 24603
18Alkylating AgentsPhase 24827
19Isophosphamide mustardPhase 2400
20AntibodiesPhase 26394
21Antibiotics, AntitubercularPhase 27180
22Anti-Bacterial AgentsPhase 211226
23Antifungal AgentsPhase 23696

Interventional clinical trials:

(show all 14)
idNameStatusNCT IDPhase
1Selinexor in Advanced LiposarcomaRecruitingNCT02606461Phase 2, Phase 3
2Rosiglitazone in Treating Patients With LiposarcomaCompletedNCT00004180Phase 2
3Study of Abemaciclib in Dedifferentiated LiposarcomaRecruitingNCT02846987Phase 2
4A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated LiposarcomaRecruitingNCT03096912Phase 2
5Ph II Cabazitaxel DD LiposarcomaRecruitingNCT01913652Phase 2
6Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated LiposarcomaRecruitingNCT02247544Phase 2
7SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced SarcomasRecruitingNCT02301039Phase 2
8Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and ChondrosarcomaRecruitingNCT02821507Phase 2
9A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated LiposarcomaActive, not recruitingNCT02571829Phase 2
10Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical TrialActive, not recruitingNCT01692496Phase 2
11Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)Not yet recruitingNCT03114527Phase 2
12Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter TrialTerminatedNCT01876043Phase 2
13Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated LiposarcomaWithdrawnNCT00969917Phase 2
14Phase 1 Safety Testing of SAR405838Active, not recruitingNCT01636479Phase 1

Search NIH Clinical Center for Dedifferentiated Liposarcoma

Genetic Tests for Dedifferentiated Liposarcoma

About this section

Anatomical Context for Dedifferentiated Liposarcoma

About this section

MalaCards organs/tissues related to Dedifferentiated Liposarcoma:

36
Bone, Lung, Colon, Liver, Adipocyte, Brain, Lymph node

Publications for Dedifferentiated Liposarcoma

About this section

Articles related to Dedifferentiated Liposarcoma:

(show top 50)    (show all 185)
idTitleAuthorsYear
1
Dedifferentiated liposarcoma of the lower extremity with low-grade dedifferentiation and low-grade osteosarcomatous component. (27909788)
2017
2
Primary Diaphragmatic Dedifferentiated Liposarcoma in a Young Female Patient after Delivery. (27247814)
2016
3
Application of MDM2 Fluorescence In Situ Hybridization and Immunohistochemistry in Distinguishing Dedifferentiated Liposarcoma From Other High-grade Sarcomas. (27028243)
2016
4
Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma. (27409346)
2016
5
Differential diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: utility of p16 in combination with MDM2 and CDK4 immunohistochemistry. (27597521)
2016
6
Dedifferentiated Liposarcoma of Sigmoid Mesocolon - A Case Report. (27604671)
2016
7
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial. (27124835)
2016
8
Primary mediastinal dedifferentiated liposarcoma resected by lateral thoracotomy with video-assisted thoracoscopic surgery. (26724326)
2016
9
Rare Aggressive Behavior of MDM2-Amplified Retroperitoneal Dedifferentiated Liposarcoma, with Brain, Lung and Subcutaneous Metastases. (27746879)
2016
10
MDM2 Expression in Extranodal Abdominal and Retroperitoneal Follicular Dendritic Cell Sarcomas, Mimicking Dedifferentiated Liposarcomas. (26180935)
2016
11
Dedifferentiated Liposarcoma: Updates on Morphology, Genetics, and Therapeutic Strategies. (26645460)
2016
12
Paratesticular dedifferentiated liposarcoma with rhabdomyoblastic differentiation and hCG production: Case study and literature review. (27773101)
2016
13
Dedifferentiated Liposarcoma Masquerading as Rhabdomyosarcoma. (27801731)
2016
14
Giant dedifferentiated liposarcoma of small bowel mesentery: a case report. (27654578)
2016
15
Plasma levels of miRNA-155 as a powerful diagnostic marker for dedifferentiated liposarcoma. (27186423)
2016
16
Spermatic cord dedifferentiated liposarcoma presenting as a recurrent inguinal hernia. (27995856)
2016
17
Homologous Lipoblastic Differentiation in Dedifferentiated Liposarcoma. (26644373)
2016
18
Multiple Primary Dedifferentiated Liposarcoma of the Jejunal Mesentery: A Case Report and Review of Literature. (26894164)
2016
19
Clinical outcome of dedifferentiated liposarcoma in the extremities: A retrospective case series of 7 patients. (27317086)
2016
20
Dedifferentiated liposarcoma involving the spleen and splenic hilum: a report of a case with a rare growth pattern. (25594652)
2015
21
Dedifferentiated Liposarcoma of the Anterior Mediastinum: A Rare Case. (26252913)
2015
22
Immunohistochemical, cytogenetic, and molecular cytogenetic characterization of both components of a dedifferentiated liposarcoma: implications for histogenesis. (25550570)
2015
23
Dedifferentiated Liposarcoma of the Gastroesophageal Junction. (25690861)
2015
24
Paratesticular dedifferentiated liposarcoma with prominent myxoid stroma: report of a case and review of the literature. (25986682)
2015
25
The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcoma. (26006023)
2015
26
Peritoneal sarcomatosis: site of origin for the establishment of an in vitro and in vivo cell line model to study therapeutic resistance in dedifferentiated liposarcoma. (26373732)
2015
27
Seaweed floating in the pericardium: a rare case of primary dedifferentiated liposarcoma. (26525285)
2015
28
Dedifferentiated Liposarcoma of the Spermatic Cord: A Series of 42 Cases. (25828386)
2015
29
Metastatic uterine leiomyosarcoma with MDM2 amplification mimicking dedifferentiated liposarcoma: a diagnostic pitfall. (25675188)
2015
30
Metastasis in dedifferentiated liposarcoma: Predictors and outcome in 148 patients. (25659772)
2015
31
SAR405838: A novel and potent inhibitor of the MDM2:p53 axis for the treatment of dedifferentiated liposarcoma. (26475335)
2015
32
Primary cardiac dedifferentiated liposarcoma with homologous and heterologous differentiation: a case report. (26464734)
2015
33
Alternative lengthening of telomeres and loss of ATRX are frequent events in pleomorphic and dedifferentiated liposarcomas. (26022452)
2015
34
Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas. (26336885)
2015
35
Dedifferentiated liposarcoma presenting as a large rectal mass. (26112679)
2015
36
Syndecan-1 regulates adipogenesis: new insights in dedifferentiated liposarcoma tumorigenesis. (25344834)
2014
37
Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models. (25500074)
2014
38
MDM2 copy numbers in well-differentiated and dedifferentiated liposarcoma: characterizing progression to high-grade tumors. (24515760)
2014
39
Retroperitoneal dedifferentiated liposarcoma lacking MDM2 amplification in a patient with a germ line CHEK2 mutation. (24595525)
2014
40
Prognostic relevance of FAcdAcration Nationale des Centres de Lutte Contre le Cancer grade and MDM2 amplification levels in dedifferentiated liposarcoma: a study of 50 cases. (25059573)
2014
41
High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma. (25628856)
2014
42
Ultrasound-guided fine-needle aspiration of a posterior neck dedifferentiated liposarcoma with MDM2 fluorescence in situ hybridization performed on a Pap-stained smear. (25132684)
2014
43
Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma. (25238053)
2014
44
Primary dedifferentiated liposarcoma of the femur presenting with malignant fibrous histiocytoma: A case report and review of the literature. (25013482)
2014
45
Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas? (24525499)
2014
46
Predictors of outcomes in patients with primary retroperitoneal dedifferentiated liposarcoma undergoing surgery. (24315890)
2014
47
Nuclear Expression of STAT6 in Dedifferentiated Liposarcomas With a Solitary Fibrous Tumor-like Morphology: A Diagnostic Pitfall. (25075469)
2014
48
Primary dedifferentiated liposarcoma of the lung with rhabdomyoblastic and chrondroblastic differentiation. (24612243)
2014
49
Loss of heterozygosity and microsatellite instability are rare in sporadic dedifferentiated liposarcoma: a study of 43 well-characterized cases. (24878023)
2014
50
An unusual case of primary colonic dedifferentiated liposarcoma. (24394854)
2014

Variations for Dedifferentiated Liposarcoma

About this section

Expression for genes affiliated with Dedifferentiated Liposarcoma

About this section
Search GEO for disease gene expression data for Dedifferentiated Liposarcoma.

Pathways for genes affiliated with Dedifferentiated Liposarcoma

About this section

Pathways related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

(show all 36)
idSuper pathwaysScoreTop Affiliating Genes
19.5MDM2, TP53
29.5CDK4, TP53
39.2CDK4, MDM2, TP53
49.2CDK4, MDM2, TP53
59.2CDK4, MDM2, TP53
69.2CDK4, MDM2, TP53
7
Show member pathways
9.2CDK4, MDM2, TP53
89.1CDKN2A, MDM2, TP53
9
Show member pathways
9.1CDKN2A, MDM2, TP53
109.1CDKN2A, MDM2, TP53
119.1CDKN2A, MDM2, TP53
129.1CDKN2A, MDM2, TP53
139.1CDKN2A, MDM2, TP53
149.1CDKN2A, MDM2, TP53
15
Show member pathways
9.1CDKN2A, MDM2, TP53
16
Show member pathways
9.1CDK4, CDKN2A, TP53
178.7CDK4, CDKN2A, MDM2, TP53
18
Show member pathways
8.7CDK4, CDKN2A, MDM2, TP53
198.7CDK4, CDKN2A, MDM2, TP53
20
Show member pathways
8.7CDK4, CDKN2A, MDM2, TP53
21
Show member pathways
8.7CDK4, CDKN2A, MDM2, TP53
22
Show member pathways
8.7CDK4, CDKN2A, MDM2, TP53
238.7CDK4, CDKN2A, MDM2, TP53
248.7CDK4, CDKN2A, MDM2, TP53
25
Show member pathways
8.7CDK4, CDKN2A, MDM2, TP53
26
Show member pathways
8.7CDK4, CDKN2A, MDM2, TP53
278.7MDM2, MET, TP53
288.7MDM2, MET, TP53
29
Show member pathways
8.7MDM2, MET, TP53
30
Show member pathways
8.4CDK4, MDM2, MET, TP53
318.4CDK4, MDM2, MET, TP53
32
Show member pathways
8.4CDK4, CDKN2A, HMGA2, MDM2, TP53
338.3HMGA2, MDM2, MET, TP53
347.9CDK4, CDKN2A, MDM2, MET, TP53
35
Show member pathways
7.9CDK4, CDKN2A, MDM2, MET, TP53
367.9CDKN2A, HMGA2, MDM2, MET, TP53

GO Terms for genes affiliated with Dedifferentiated Liposarcoma

About this section

Cellular components related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1senescence-associated heterochromatin focusGO:00359859.6CDKN2A, HMGA2

Biological processes related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

(show all 17)
idNameGO IDScoreTop Affiliating Genes
1negative regulation of cell cycle arrestGO:007115710.5CDK4, MDM2
2adipose tissue developmentGO:006061210.5CDK4, HMGA2
3positive regulation of cellular senescenceGO:200077410.3CDKN2A, HMGA2
4muscle filament slidingGO:003004910.3ACTC1, DES
5cellular response to actinomycin DGO:007271710.3MDM2, TP53
6cellular response to gamma radiationGO:007148010.3MDM2, TP53
7base-excision repairGO:000628410.2HMGA2, TP53
8positive regulation of cell cycle arrestGO:007115810.1HMGA2, TP53
9positive regulation of protein export from nucleusGO:004682710.0MDM2, TP53
10replicative senescenceGO:00903999.8CDKN2A, TP53
11senescence-associated heterochromatin focus assemblyGO:00359869.6CDKN2A, HMGA2
12response to antibioticGO:00466779.5MDM2, TP53
13cell cycleGO:00070499.4CDK4, CDKN2A, HMGA2, TP53
14negative regulation of transcription, DNA-templatedGO:00458929.4CDKN2A, HMGA2, MDM2, TP53
15negative regulation of apoptotic processGO:00430669.4ACTC1, HMGA2, MDM2, TP53
16positive regulation of apoptotic processGO:00430659.3CDK4, CDKN2A, HMGA2, TP53
17positive regulation of gene expressionGO:00106289.1ACTC1, HMGA2, MDM2, TP53

Molecular functions related to Dedifferentiated Liposarcoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1disordered domain specific bindingGO:00977189.9MDM2, TP53
2SUMO transferase activityGO:00197899.7CDKN2A, MDM2

Sources for Dedifferentiated Liposarcoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet